Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma.
Kinget L, Naulaerts S, Govaerts J, Vanmeerbeek I, Sprooten J, Laureano RS, Dubroja N, Shankar G, Bosisio FM, Roussel E, Verbiest A, Finotello F, Ausserhofer M, Lambrechts D, Boeckx B, Wozniak A, Boon L, Kerkhofs J, Zucman-Rossi J, Albersen M, Baldewijns M, Beuselinck B, Garg AD. Kinget L, et al. Nat Med. 2024 May 21. doi: 10.1038/s41591-024-02978-9. Online ahead of print. Nat Med. 2024. PMID: 38773341
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.
Montemagno C, Jacquel A, Pandiani C, Rastoin O, Dawaliby R, Schmitt T, Bourgoin M, Palenzuela H, Rossi AL, Ambrosetti D, Durivault J, Luciano F, Borchiellini D, Le Du J, Gonçalves LCP, Auberger P, Benhida R, Kinget L, Beuselinck B, Ronco C, Pagès G, Dufies M. Montemagno C, et al. Among authors: kinget l. J Exp Clin Cancer Res. 2024 Mar 19;43(1):86. doi: 10.1186/s13046-024-02984-2. J Exp Clin Cancer Res. 2024. PMID: 38504270 Free PMC article.
Trial watch: chemotherapy-induced immunogenic cell death in oncology.
Sprooten J, Laureano RS, Vanmeerbeek I, Govaerts J, Naulaerts S, Borras DM, Kinget L, Fucíková J, Špíšek R, Jelínková LP, Kepp O, Kroemer G, Krysko DV, Coosemans A, Vaes RDW, De Ruysscher D, De Vleeschouwer S, Wauters E, Smits E, Tejpar S, Beuselinck B, Hatse S, Wildiers H, Clement PM, Vandenabeele P, Zitvogel L, Garg AD. Sprooten J, et al. Among authors: kinget l. Oncoimmunology. 2023 Jun 3;12(1):2219591. doi: 10.1080/2162402X.2023.2219591. eCollection 2023. Oncoimmunology. 2023. PMID: 37284695 Free PMC article. Review.
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, Govaerts J, Naulaerts S, Berneman ZN, Beuselinck B, Bol KF, Borst J, Coosemans A, Datsi A, Fučíková J, Kinget L, Neyns B, Schreibelt G, Smits E, Sorg RV, Spisek R, Thielemans K, Tuyaerts S, De Vleeschouwer S, de Vries IJM, Xiao Y, Garg AD. Laureano RS, et al. Among authors: kinget l. Oncoimmunology. 2022 Jul 4;11(1):2096363. doi: 10.1080/2162402X.2022.2096363. eCollection 2022. Oncoimmunology. 2022. PMID: 35800158 Free PMC article.
Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study.
Demasure S, Spriet I, Debruyne PR, Laenen A, Wynendaele W, Baldewijns M, Dumez H, Clement PM, Wildiers H, Schöffski P, Roussel E, Kinget L, Albersen M, Beuselinck B. Demasure S, et al. Among authors: kinget l. Acta Oncol. 2022 Jan;61(1):22-29. doi: 10.1080/0284186X.2021.1989720. Epub 2021 Oct 28. Acta Oncol. 2022. PMID: 34711121
Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials.
Roussel E, Verbiest A, Kinget L, Boeckx B, Zucman-Rossi J, Couchy G, Caruso S, Job S, de Reyniès A, De Wever L, Baldewijns M, Van Poppel H, Joniau S, Lambrechts D, Albersen M, Beuselinck B. Roussel E, et al. Among authors: kinget l. Clin Genitourin Cancer. 2021 Dec;19(6):e382-e394. doi: 10.1016/j.clgc.2021.07.005. Epub 2021 Jul 10. Clin Genitourin Cancer. 2021. PMID: 34362692
14 results